Rate My Professor Courtney Miller

The Miller Lab integrates two branches: in vivo studies of memory neurobiology and neuropsychiatric disorders, alongside drug discovery and development for cancer therapeutics. In 2020, Miller co-founded Myosin Therapeutics with colleagues Patrick Griffin, Ph.D., and Ted Kamenecka, Ph.D., to translate her discoveries into clinical therapies. Key compounds include MT-110, a first-in-class drug for methamphetamine use disorder funded by a $2.8 million NIH Small Business Innovation Research fast-track grant in 2021, and MT-125, a glioblastoma candidate that inhibits tumor invasion via non-muscle myosin IIA and blocks cell division via non-muscle myosin IIB, increasing radiation sensitivity and achieving 40% survival in mouse models when combined with radiation and an FDA-approved drug. Her influential publications include "Development of clinically viable non-muscle myosin II small molecule inhibitors" (Cell, 2025), "Multiple memory object-drug association task (MODAT) for the study of polydrug associations" (Addiction Neuroscience, 2025), "Discovery of Selective Inhibitors for In Vitro and In Vivo Interrogation of Skeletal Myosin II" (ACS Chemical Biology, 2021), "Social stress‐potentiated methamphetamine seeking" (Addiction Biology, 2018), and "Cortical DNA methylation maintains remote memory" (Nature Neuroscience, 2010). Miller earned BioFlorida’s 2022 Weaver H. Gaines Entrepreneur of the Year award for advancing Florida's life sciences industry through innovative therapies for cancer and psychiatric disorders.